



Prior Authorization Approval Criteria

Adcetris (brentuximab)

Generic name:	brentuximab
Brand name:	Adcetris
Medication class:	Antineoplastic; antibody-microtubule inhibitor conjugate
FDA-approved uses:	<ul style="list-style-type: none">• Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients that are not candidates for autologous stem cell transplant.• Anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen
Available dosage forms:	50mg single-use vials
Usual dose:	1.8mg/kg IV infusion every 3 weeks; maximum 16 cycles
Approximate cost: (based on AWP 2011)	\$16,200 per cycle
Duration of therapy:	16 cycles

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Complete blood count is obtained prior to therapy
- Approval will be for 4 cycles at a time (3 months)
- Eastern Cooperative Oncology Group performance status ≤ 2
- Hodgkin lymphoma
 - Failure of autologous stem cell transplantOR
 - Failure of at least two prior multi-agent chemotherapy regimens in patients that are not candidates for autologous stem cell transplant
- Anaplastic large cell lymphoma
 - Failure of at least one prior multi-agent chemotherapy regimen

Criteria for continuation of therapy:

- Patient's disease has not progressed
- Patient has not experienced unacceptable toxicity
- Patient has not exceeded 16 cycles of therapy

Caution:

- Peripheral neuropathy
- Infusion reactions
- Neutropenia
- Tumor lysis syndrome

Monitoring:

- Complete blood count prior to each infusion

Not approved if:

- Does not meet the above criteria

Special considerations:

- Medical Benefit
- For patients with weight >100kg, dose should be calculated for 100kg

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 12/14/11